Is prostate-specific antigen density superior than prostate-specific antigen kinetics and prostate volume in predicting clinically insignificant prostate cancer?

Year 2024, EARLY ONLINE, 1 - 8

Sinan Avcı , Özgür Ekici , Volkan Çağlayan , Abdullah Erdoğan , Efe Önen , Uğur Akgün , Rıdvan Özcan , Sedat Öner

https://doi.org/10.18621/eurj.1489083

Abstract

Objectives: In this study, we aimed to evaluate the parameters that could predict clinically insignificant prostate cancer (ciPCa) in men who underwent transrectal ultrasound (TRUS)-guided prostate biopsy.

Methods: Data of patients who underwent transrectal prostate biopsy between January 2015 and November 2019 were examined retrospectively. Free/total PSA ratio (fPSA%), serum total and free prostate-specific antigen (PSA) levels, prostate volumes (PV) measured by ultrasonography, and PSA density (PSAD) values of the patients before biopsy were recorded. ciPCa patients were defined as patients with Gleason scores ≤6 and clinical stage ≤T2a (Group 1). The remaining patients (Gleason score >6 and clinical stage >T2a) were included in Group 2 (clinical significant prostate cancer (csPCa). The parameters examined before biopsy were compared between groups.

Results: After performing the exclusion criteria, the study counts in 168 patients with the current data of total/free PSA levels, age, PV calculated by TRUS, rectal examination findings, and pathology reports. Group 1 consisted of 115 patients and Group 2 consisted of 53 patients. In the univariate analysis, PV, total PSA and PSAD were found significantly different between groups, while age, free PSA, and fPSA% showed no significant difference between the two groups. According to the results of the multivariate analysis, the independent predictor of ciPCa was determined to be PSAD while total PSA and PV were not independent predictors.

Conclusion: PSAD was found to be superior to other PSA kinetics in predicting ciPCa.

Keywords

Prostate-specific antigen, prostate cancer, prostate-specific antigen density, prostate volume

References

• 1. Heidenreich A, Aus G, Bolla M, et al; European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68-80. doi: 10.1016/j.eururo.2007.09.002.
• 2. Javaeed A, Ghauri SK, Ibrahim A, Doheim MF. Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review. Oncol Rev. 2020;14(1):449. doi: 10.4081/oncol.2020.449.
• 3. Okegawa T, Kinjo M, Watanabe K, et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL. BJU Int. 2000;85(6):708-714. doi: 10.1046/j.1464-410x.2000.00602.x.
• 4. Bruno SM, Falagario UG, d'Altilia N, et al. PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. Front Oncol. 2021;11:693684. doi: 10.3389/fonc.2021.693684.
• 5. Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019;74(1):135-145. doi: 10.1111/his.13712.
• 6. Derin O, Fonseca L, Sanchez-Salas R, Roberts MJ. Infectious complications of prostate biopsy: winning battles but not war. World J Urol. 2020;38(11):2743-2753. doi: 10.1007/s00345-020-03112-3.
• 7. Ali A, Hoyle A, Baena E, Clarke NW. Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis. Curr Opin Urol. 2017;27(3):217-224. doi: 10.1097/MOU.0000000000000385.
• 8. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol. 2007;177(2):505-509. doi: 10.1016/j.juro.2006.09.039.
• 9. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147(3 Pt 2):815-816. doi: 10.1016/s0022-5347(17)37393-7.
• 10. Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10(1):20015. doi: 10.1038/s41598-020-76786-9.
• 11. Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate. 2020;80(16):1444-1449. doi: 10.1002/pros.24078.
• 12. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):57-63. doi: 10.1038/s41391-017-0024-7.
• 13. Kosaka T, Mizuno R, Shinojima T, et al. The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years. Am J Clin Exp Urol. 2014;2(4):332-336.
• 14. Distler FA, Radtke JP, Bonekamp D, et al. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction. J Urol. 2017;198(3):575-582. doi: 10.1016/j.juro.2017.03.130.
• 15. Gao XD, Miao Q, Zhang JL, et al. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml-1 in Western China. Asian J Androl. 2022;24(2):195-200. doi: 10.4103/aja202182.
• 16. Shore ND, Pieczonka CM, Henderson RJ, et al. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial. Urol Oncol. 2020;38(8):683.e1-683.e10. doi: 10.1016/j.urolonc.2020.03.011.
• 17. Erdogan A, Polat S, Keskin E, Turan A. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? Aging Male. 2020;23(1):59-65. doi: 10.1080/13685538.2019.1578741.
• 18. Chen ME, Troncoso P, Johnston D, Tang K, Babaian RJ. Prostate cancer detection: relationship to prostate size. Urology. 1999;53(4):764-768. doi: 10.1016/s0090-4295(98)00574-3.
• 19. Huang D, Wu YS, Ye DW, et al. Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. Asian J Androl. 2020;22(5):539-543. doi: 10.4103/aja.aja_136_19.